Bitte warten ...
 

European MCL Younger

Efficacy of 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and autologous stem cell transplantation versus alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation

Kategorie: Indolente Lymphome/MCL

Clinical Trials Register (clinicaltrials.gov)

Leitung: Herr Prof. Dr. med. Martin Dreyling

 

Herr Prof. Dr. med. Martin Dreyling

Klinikum der Universität München

E-Mail senden

Informationen zur Studie

Studientherapie

standard arm: 6 cycles CHOP plus Rituximab followed by myeloablative radiochemotherapy (12 Gray TBI, cyclo 2x 60 mg/m2) and autologous stem cell transplantation
experimental arm: alternating cycles of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative radiochemotherapy (10 Gray TBI, Ara-C, Melphalan) and autologous stem cell transplantation

Studienstatus

Abgeschlossen

Indikation

Mantelzell- Lymphom

Anzahl Patienten

497

Alter der Patienten

Studienphase

Phase III

Zusatzinformationen

Allgemeine Infos zum Antrag

Primäres Ziel der Studie

The study addresses the impact of CHOP and high dose ARA-C plus anti-CD20 (Rituximab) during induction followed by a high dose ARA-C containing myeloablative radio-chemotherapy regimen and autologous blood stem cell transplantation on time to treatment failure, complete response rate, progression-free and overall survival in comparison to CHOP plus Rituximab followed by the standard myeloablative radio-chemotherapy and PBSCT.

Studienpopulation

The current study is designed for previously untreated patients at 18 to 65 years of age with advanced stage mantle cell lymphomas.

Primäre Endpunkte

time to treatment failure

Sekundäre Endpunkte

complete remission rate (CR-rate)
overall response rate (OR-rate)
progression-free survival (PFS)
overall survival (OS)
toxicity
minimal residual disease (MRD)

Spezifische Infos zum Antrag

Therapie
Biomarker-Programm geplant

Ja

Publikationen

Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network

23.10.2024

Jiang L, Dreyling M, Hermine O, Mansmann U, Walewski J, Ribrag V, Thieblemont C, Pott C, Bachy E, Feugier P, Hübel K, Schumacher M*, Hoster E*

DOI: 10.1111/bjh.19854

Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials

16.09.2024

Khouja M, Jiang L, Pal K, Stewart PJ, Regmi B, Schwarz M, Klapper W, Alig SK, Darzentas N, Kluin-Nelemans HC, Hermine O, Dreyling M, Gonzalez de Castro D, Hoster E, Pott C

DOI: 10.1038/s41375-024-02375-8

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)

26.07.2023

Scheubeck G, Jiang L, Hermine O, Kluin-Nelemans HC, Schmidt C, Unterhalt M, Rosenwald A, Klapper W, Evangelista A, Ladetto M, Jerkeman M, Ferrero S, Dreyling M, Hoster E

DOI: 10.1038/s41375-023-01977-y

High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network

05.12.2022

Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, Hubel K, Haioun C, Casasnovas RO, Schmidt C, Bouabdallah K, Ribrag V, Kanz L, Durig J, Metzner B, Sibon D, Cheminant M, Burroni B, Klapper W, Hiddemann W, Unterhalt M, Hoster E*, Dreyling M*

DOI: 10.1200/JCO.22.01780

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma

19.09.2022

Villa D*, Hoster E*, Hermine O, Klapper W, Szymczyk M, Bosly A, Unterhalt M, Rimsza LM, Ramsower C, Freeman CL, Scott DW, Gerrie AS, Savage KJ, Sehn LH, Dreyling M

DOI: 10.1182/bloodadvances.2022007371

A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

31.12.2021

Zaccaria GM, Ferrero S, Hoster E, Passera R, Evangelista A, Genuardi E, Drandi D, Ghislieri M, Barbero D, Del Giudice I, Tani M, Moia R, Volpetti S, Cabras MG, Di Renzo N, Merli F, Vallisa D, Spina M, Pascarella A, Latte G, Patti C, Fabbri A, Guarini A, Vitolo U, Hermine O, Kluin-Nelemans HC, Cortelazzo S, Dreyling M, Ladetto M

DOI: 10.3390/cancers14010188

LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome

10.06.2021

Thurner L, Fadle N, Bittenbring JT, Regitz E, Schuck R, Cetin O, Stuhr A, Rixecker T, Murawski N, Poeschel V, Kaddu-Mulindwa D, Preuss KD, Stilgenbauer S, Hermine O, Kluin-Nelemans HC, Hartmann S, Dreyling M, Pott C, Bewarder M,* Hoster E*

DOI: 10.1182/blood.2020008835

The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial

07.07.2020

Roider T, Wang X, Huttl K, Muller-Tidow C, Klapper W, Rosenwald A, Stewart JP, de Castro DG, Dreger P, Hermine O, Kluin-Nelemans HC, Grabe N, Dreyling M, Pott C, Ott G, Hoster E, Dietrich S

DOI: 10.1002/ijc.33202

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

08.11.2018

Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E*, Vitolo U*

DOI: 10.1111/bjh.15643

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network

10.08.2018

Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E*, Rosenwald A*

DOI: 10.1111/bjh.15519

Expression of TP53 is associated with outcome of MCL independent of MIPI and Ki-67 in trials of the European-MCL Network

01.12.2017

Aukema, S. M.*, Hoster, E.*, Rosenwald, A., Canoni, D., Delfau-Larue, M. H., Rymkiewicz, G., Thorns, C., Hartmann, S., Kluin-Nelemans, H., Hermine, O., Dreyling, M.*, Klapper, W.*

DOI: 10.1182/blood-2017-07-797019

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

06.08.2016

Hermine O*, Hoster E*, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hanel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Duhrsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M

DOI: 10.1016/S0140-6736(16)00739-X

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study

01.03.2016

Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A, Delfau-Larue MH, Lhermitte L, Thieblemont C, Ribrag V, Cheze S, Sanhes L, Jardin F, Lefrere F, Delarue R, Hoster E, Dreyling M, Asnafi V, Hermine O, Macintyre E

DOI: 10.3324/haematol.2015.134957

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

29.02.2016

Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH, Klapper W

DOI: 10.1200/JCO.2015.63.8387

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

24.11.2015

Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Raty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O

DOI: 10.1038/leu.2015.322

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

28.05.2015

Delfau-Larue MH, Klapper W, Berger F, Jardin F, Briere J, Salles G, Casasnovas O, Feugier P, Haioun C, Ribrag V, Thieblemont C, Unterhalt M, Dreyling M, Macintyre E, Pott C, Hermine O, Hoster E

DOI: 10.1182/blood-2015-02-628792

Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network

31.03.2014

Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, Trneny M, Geisler CH, Di Raimondo F, Szymczyk M, Stilgenbauer S, Thieblemont C, Hallek M, Forstpointner R, Pott C, Ribrag V, Doorduijn J, Hiddemann W, Dreyling MH, Unterhalt M

DOI: 10.1200/JCO.2013.52.2466

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

22.04.2010

Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Böttcher S, Asnafi V, Plonquet A, Siebert R, Callet-Bauchu E, Andersen N, van Dongen JJ, Klapper W, Berger F, Ribrag V, van Hoof AL, Trneny M, Walewski J, Dreger P, Unterhalt M, Hiddemann W, Kneba M, Kluin-Nelemans HC, Hermine O, Macintyre E, Dreyling M

DOI:10.1182/blood-2009-06-230250

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations

01.04.2008

Bottcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E, Hiddemann W, Unterhalt M, Dreyling M, Siebert R, Kneba M, Pott C

DOI: 10.3324/haematol.11267